|Other Names||Transcription factor E3, Class E basic helix-loop-helix protein 33, bHLHe33, TFE3, BHLHE33|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Transcription factor that specifically recognizes and binds E-box sequences (5'-CANNTG-3'). Efficient DNA-binding requires dimerization with itself or with another MiT/TFE family member such as TFEB or MITF. In association with TFEB, activates the expression of CD40L in T-cells, thereby playing a role in T- cell-dependent antibody responses in activated CD4(+) T-cells and thymus-dependent humoral immunity. Specifically recognizes the MUE3 box, a subset of E-boxes, present in the immunoglobulin enhancer. It also binds very well to a USF/MLTF site.|
|Tissue Location||Ubiquitous in fetal and adult tissues.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The microphthalmia transcription factor/transcriptionfactor E (MITF-TFE) family of basic helix-loop-helix leucine zipper(bHLH-Zip) transcription factors includes four family members:MITF, TFE3, TFEB and TFEC. The TEF3 protein encoded by this geneactivates transcription through binding to the muE3 motif of theimmunoglobulin heavy-chain enhancer. The TFEC protein formsheterodimers with the TEF3 protein and inhibits TFE3-dependenttranscription activation. The TEF3 protein interacts withtranscription regulators such as E2F3, SMAD3, and LEF-1, and isinvolved in TGF-beta-induced transcription, playing important rolesin cell growth, proliferation, and osteoclast and macrophagedifferentiation. The TFE3 protein also activates hepatic IRS-2gene, and induces hexokinase II (HK2) and insulin-induced gene 1(INSIG1); it participates in insulin signaling and could be atherapeutic target for diabetes. This gene is also involved inchromosomal translocations, resulting in different fusion geneproducts in papillary renal cell carcinomas and alveolar soft partsarcomas, such as PRCC-TFE3, RCC17-TFE3, PSF-TFE3, NonO(p54nrb)-TFE3 and ASPL-TFE3.
Argani, P., et al. Am. J. Surg. Pathol. 34(10):1395-1406(2010)Haudebourg, J., et al. Cancer Genet. Cytogenet. 200(2):75-78(2010)Chang, I.W., et al. Am. J. Surg. Pathol. 33(12):1894-1901(2009)Yamaguchi, T., et al. Acta Cytol. 53(6):693-697(2009)Kuroda, N., et al. Pathol. Int. 59(10):769-770(2009)
If you have any additional inquiries please email technical services at email@example.com.